Michael Rubin

Mike Rubin is the Founder and CEO of Northpond Ventures, a leading science, medical, and technology-driven venture capital firm. Mike is currently a board director at DNA Nexus, Inflammatix, Intabio, Scipher, Sherlock, SpeeDx, and Teckro. Mike was previously co-founder and managing partner of Sands Capital Ventures, a global cross-industry venture capital business, and affiliate of Sands Capital Management. Under his leadership, Sands Capital Ventures invested in a large number of leading businesses in multiple industries and geographies. Investments in biotechnology, life sciences, and diagnostics included: Acessa Health Inc.; Agilis Biotherapeutics, LLC (Sold to PTC Therapeutics); Avitide, Inc.; Complete Genomics, Inc. (IPO; Sold to BGI Genomics); Day Zero Diagnostics, Inc.; Dova Pharmaceuticals (IPO); Firefly BioWorks (Sold to Abcam); Genometry, Inc.; Mitra Biotech; NanoView Biosciences; Quad Technologies (Sold to Bio-Techne Corporation); and QVella Corporation. Information technology investments included: Anaplan (IPO); AppDynamics (Sold to Cisco); DocuSign (IPO); Health Catalyst (IPO); Kit Check, Inc.; Modernizing Medicine, Inc.; Mulesoft, LLC (Sold to Salesforce); Scopely, Inc.; and Teckro, Inc. Investments in financial technology included: Funding Circle (IPO); LendingClub (IPO); Upgrade, Inc.; Neptune Financial Inc.; and Paydiant, Inc. (Sold to PayPal). Global internet franchises included: BigBasket; Blackbuck; and Souq (Sold to Amazon). Prior to joining Sands Capital Ventures, Mike became a board certified physician and surgeon, and completed his fellowship training at Harvard Medical School. Mike also holds an MBA from The University of Massachusetts Amherst, is a CFA charterholder, earned his medical doctorate at The University of Chicago, and holds a BS in Electrical Engineering from The UCLA Samueli School of Engineering, where he was the student graduation speaker.